Plasminogen Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Intravenous Injection, Eye Drops), By Application (Ligneous Conjunctivitis, Diabetic Foot, Wound Healing, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.79 Billion
CAGR (2026-2031)	5.42%
Fastest Growing Segment	Eye Drops
Largest Market	North America
Market Size (2031)	USD 3.83 Billion

Market Overview

The Global Plasminogen Market will grow from USD 2.79 Billion in 2025 to USD 3.83 Billion by 2031 at a 5.42% CAGR. Plasminogen is a glycoprotein zymogen that converts to plasmin, an enzyme essential for fibrinolysis and wound healing, with the market centering on therapeutic concentrates for treating congenital Type I plasminogen deficiency and ligneous conjunctivitis. The primary drivers supporting market growth include the increasing identification of rare coagulation disorders through advanced genetic screening and the expanded regulatory approval of specific replacement therapies. These fundamental medical necessities establish a sustainable demand foundation that differs significantly from transient market trends.

Nevertheless, the sector encounters a significant challenge regarding the finite supply of source plasma and the high capital barriers associated with fractionation, which restricts the number of capable manufacturers. This consolidation limits supply elasticity and maintains high therapy costs. According to the 'Plasma Protein Therapeutics Association', in '2024', member companies produced more than 60 percent of the plasma protein therapies used worldwide. This centralized production capacity highlights the supply chain vulnerability that may impede broader market expansion and accessibility.

Key Market Drivers

Regulatory approvals for novel replacement therapies and the strategic expansion of manufacturing infrastructure are the primary forces propelling the global plasminogen market. The transition from compounding pharmacy formulations to FDA-approved biologicals requires immense capital investment in fractionation facilities to ensure a consistent supply. A pivotal development occurred when, according to Kedrion Biopharma, November 2024, in a corporate press release, the U.S. FDA approved the company’s manufacturing facility in Bolognana, Italy, to produce Ryplazim. This milestone allows for production scaling to meet global demand, overcoming supply bottlenecks. The high barriers to entry are evidenced by the financial scale required; according to Kedrion Biopharma, April 2024, in the 'Annual Report 2023', the company generated revenues of 1.4 billion Euro, highlighting the consolidated nature of players capable of sustaining such specialized operations.

Simultaneously, the expansion of clinical indications in ophthalmology is acting as a critical catalyst for increasing patient diagnosis. Ligneous conjunctivitis is often the sentinel symptom leading to the identification of the underlying congenital deficiency. According to Kedrion Biopharma, May 2024, in the 'Ryplazim Now Available in US' announcement, approximately 81 percent of patients with congenital plasminogen deficiency develop lesions on one or both eyes as their lead symptom. By focusing on this presentation, clinicians are narrowing the diagnostic gap. This clinical focus accelerates patient identification and establishes a clear medical necessity that drives insurance reimbursement and consistent market uptake for lifelong replacement therapies.

Download Free Sample Report

Key Market Challenges

The Global Plasminogen Market faces a substantial obstacle due to the finite supply of source plasma and the intense capital requirements for fractionation. These barriers effectively limit the number of capable manufacturers, leading to a consolidated market structure where supply cannot easily adjust to rising demand. This rigidity creates a low supply elasticity, maintaining high costs for therapies and restricting accessibility for patients, particularly in regions without established domestic collection capabilities.

This concentration of production and collection infrastructure introduces critical vulnerabilities into the supply chain. The market's growth is directly hampered by the geographic imbalance of plasma availability, which limits the volume of raw material available for processing. According to the 'Plasma Protein Therapeutics Association', in '2024', member companies operated approximately 160 plasma donation centers in the European Union. This relatively low number of local collection points in a major market underscores the heavy reliance on imported plasma, which creates logistical bottlenecks. Consequently, the inability to rapidly scale raw material collection in diverse regions serves as a hard ceiling on the industry's expansion potential.

Key Market Trends

The Expansion of Clinical Applications into Diabetic Foot Ulcer and Wound Care Management represents a transformative shift for the Global Plasminogen Market, moving the industry beyond its traditional focus on rare congenital deficiencies toward high-volume chronic indications. Manufacturers are increasingly leveraging the pro-inflammatory and immunoregulatory properties of plasminogen to develop regenerative therapies for non-healing wounds, a segment with a substantially larger addressable patient population than Type I deficiency. This strategic diversification allows companies to mitigate the risks associated with niche orphan markets by targeting the urgent medical necessity of diabetic complications. Validating this commercial trajectory, according to Omnio AB, May 2025, in the 'Omnio raises €4.3 Million to accelerate wound-healing drug to clinical stage' press release, the company secured €4.3 million to finalize GMP manufacturing and advance its recombinant plasminogen candidate into clinical trials specifically for chronic wound management.

The Establishment of Cross-Border Partnerships for Expanded Commercial Distribution is simultaneously reshaping the market's logistical framework to overcome the accessibility barriers inherent to rare disease therapies. As production consolidates among a limited number of global fractionators, companies are forging strategic alliances with specialized distributors to ensure consistent product availability across international jurisdictions. These collaborations are essential for navigating complex reimbursement landscapes and maintaining the cold chain integrity required for biologicals, thereby bridging the gap between centralized manufacturing and dispersed patient populations. Exemplifying this trend, according to Kedrion Biopharma, March 2025, in the 'Kedrion Expands Ryplazim Distribution Network' announcement, the company integrated three major specialty pharmacy partners, including CuraScript SD and CVS Health, into its United States network to optimize patient access to its plasminogen replacement therapy.

Segmental Insights

The Eye Drops segment is recognized as the fastest-growing category within the Global Plasminogen Market, primarily driven by the critical need to effectively treat Ligneous Conjunctivitis. This rare condition represents the most common clinical manifestation of congenital plasminogen deficiency, characterized by the formation of woody, fibrin-rich lesions on the ocular surface. The segment's rapid expansion is underpinned by the superior clinical outcomes of topical plasminogen therapies, which dissolve these pseudomembranes more efficiently than surgical interventions. Furthermore, the European Medicines Agency (EMA) has acknowledged this significant unmet medical need through orphan drug designations for ophthalmic plasminogen formulations, thereby accelerating product development and market adoption in this specialized sector.

Regional Insights

North America maintains a leading position in the global plasminogen market, driven by advanced healthcare infrastructure and high diagnosis rates for congenital deficiencies. The market expansion is significantly supported by favorable regulatory developments, such as the approval of specific plasminogen replacement therapies by the United States Food and Drug Administration (FDA). Additionally, the region benefits from a robust network for plasma collection and established reimbursement frameworks for rare disease treatments. These factors collectively ensure widespread availability and adoption of necessary therapies, establishing North America as the primary regional market.

Recent Developments

• In November 2024, Kedrion Biopharma received approval from the U.S. Food and Drug Administration (FDA) for its manufacturing facility in Bolognana, Italy, to produce Ryplazim. This regulatory milestone allowed the company to expand its global production capacity for the plasma-derived human plasminogen therapy. The Chief Commercial Officer and U.S. General Manager of Kedrion Biopharma noted that this approval was a pivotal moment that would enable the company to meet the growing demand for the treatment and better serve the global community of patients suffering from Plasminogen Deficiency type 1.
• In September 2024, Kedrion Biopharma showcased its ongoing commitment to the plasminogen deficiency community by sponsoring and presenting at the National Bleeding Disorders Foundation (NBDF) 76th Annual Bleeding Disorders Conference. The company hosted a "Campfire presentation" detailing the results of the 2nd Annual Plasminogen Deficiency Roundtable. This engagement focused on sharing information about therapy developments and fostering connections among patients, researchers, and healthcare professionals to improve care for individuals living with this rare condition.
• In May 2024, Kedrion Biopharma announced the commercial availability of its plasminogen replacement therapy, Ryplazim (plasminogen, human-tvmh), for patients in the United States. This product is the first and only FDA-approved treatment for Congenital Plasminogen Deficiency (PLGD-1), an ultra-rare genetic disorder that causes the formation of fibrin-rich lesions on mucosal surfaces. The Chief Commercial Officer of Kedrion Biopharma stated that the company was expediting production and distribution to ensure that both adult and pediatric patients could access this critical therapy, which addresses the root cause of the deficiency.
• In February 2024, Omnio AB, a Swedish biopharmaceutical company, reported significant progress in its research regarding plasminogen-based wound care. The company completed the preparation of a detailed project plan and financial model to secure funding from the European Innovation Council (EIC) Accelerator program. This development aimed to advance the commercialization of their plasminogen therapy, which is designed to treat chronic non-healing wounds such as diabetic foot ulcers. The company collaborated with external consultants to finalize the proposal, marking a key step in their strategy to bring this novel regenerative treatment to clinical trials.

Key Market Players

• Boehringer Ingelheim Inc. GmbH
• Kedrion S.p.A
• Genentech
• Prometic Life Sciences Inc
• Grifols, S.A
• Octapharma AG
• Green Cross Corporation
• Baxter International Inc.
• CSL Behring LLC
• Renaissance Acquisition Holdings LLC

By Type	By Application	By Region
Intravenous Injection Eye Drops	Ligneous Conjunctivitis Diabetic Foot Wound Healing Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Plasminogen Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Plasminogen Market , By Type:

• Intravenous Injection
• Eye Drops

• Plasminogen Market , By Application:

• Ligneous Conjunctivitis
• Diabetic Foot
• Wound Healing
• Others

• Plasminogen Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE